- Stocks Likely Don't Need Santa to Keep Rally Going
- Ford Says November Sales Rise; Crossover Cars Do Well
- Larry Kudlow's Open Letter to Tiger Woods
- Pending Home Sales Have Record Rise; Construction Flat
- AIG Slashes US Debt Under Deal With New York Fed
- Commercial Property Fears Are Overblown: Zell, LeFrak
- Trump: Time to Force Banks to Start Lending
- Accused Fraudster Rothstein Arrested
- Seamstress Fined $5.7 Million for Insider Trading
MOST SHARED
- Commercial Property Fears Are Overblown: Zell, LeFrak
- Pending Home Sales Have Record Rise; Construction Flat
- US Manufacturing Grew Less Than Expected in November
- Somali Sea Gangs Create Pirate Stock Exchange
- Good Sign for the Economy: 'Greed' Makes a Comeback
- More Late on Auto Loan Payments in Third Quarter
- AIG Slashes US Debt Under Deal With New York Fed
- Euro Zone Manufacturing Grows Faster Than Forecast
- Trump: Time to Force Banks to Start Lending
Text Size 
NEW YORK, Nov 10 (Reuters) - Regeneron Pharmaceuticals Inc and French drugmaker Sanofi-aventis said on Tuesday they have expanded their partnership to develop a number of Regeneron's experimental drugs. Sanofi will increase its annual funding to Regeneron to $160 million from $100 million beginning in 2010, and the funding will extend through 2017. The agreement extends a previous deal that was scheduled to expire at the end of 2012. The companies aim to advance an average of four to five drug candidates into clinical development each year. Regeneron's experimental drug aflibercept is now being tested in late-stage clinical trials, in partnership with Sanofi, in lung cancer, prostate cancer and colorectal cancer. To date, Regeneron and Sanofi have moved four experimental drugs into clinical development. Regeneron, which is based in the suburban New York village of Tarrytown, is also developing drugs for gout and macular degeneration -- a leading cause of blindness. Regeneron's shares closed up 12 cents at $15.80 on Tuesday on the Nasdaq. (Reporting by Toni Clarke, editing by Matthew Lewis) Keywords: REGENERON/ (toni.clarke@thomsonreuters.com; + 1 617-856-4340; Reuters Messaging: toni.clarke.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Print
Email
- Goldman Sachs has forbidden employees from gathering in private holiday parties of 12 or more.
- What do the gifts from the 12 Days of Christmas cost this year, and how do they compare to 2008?
- A conservative author aims to remind readers why capitalism works for the common good.
- Heavily armed pirates in Somalia have set up a sort of stock exhange to fund their hijackings.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- A famed author has written all his work on an old typewriter that is now up for auction. The NYT reports.
Data is a real-time snapshot *Data is delayed at least 15 minutes